

Jourik A Gietema

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7482267/publications.pdf>

Version: 2024-02-01

36
papers

1,653
citations

361413

20
h-index

330143

37
g-index

37
all docs

37
docs citations

37
times ranked

3019
citing authors

#	ARTICLE	IF	CITATIONS
1	Shared-care survivorship program for testicular cancer patients: safe and feasible. <i>ESMO Open</i> , 2022, 7, 100488.	4.5	2
2	Genome-wide association study of cardiovascular disease in testicular cancer patients treated with platinum-based chemotherapy. <i>Pharmacogenomics Journal</i> , 2021, 21, 152-164.	2.0	4
3	Dose-Dependent Effect of Platinum-Based Chemotherapy on the Risk of Metachronous Contralateral Testicular Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 319-327.	1.6	15
4	Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 1553-1562.	1.6	83
5	Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 1563-1574.	1.6	108
6	Cognitive Impairment in Long-Term Survivors of Testicular Cancer More Than 20 Years after Treatment. <i>Cancers</i> , 2021, 13, 5675.	3.7	2
7	Heart failure after treatment for breast cancer. <i>European Journal of Heart Failure</i> , 2020, 22, 366-374.	7.1	28
8	Myocardial dysfunction in long-term breast cancer survivors treated at ages 40-50 years. <i>European Journal of Heart Failure</i> , 2020, 22, 338-346.	7.1	25
9	Platinum exposure and cause-specific mortality among patients with testicular cancer. <i>Cancer</i> , 2020, 126, 628-639.	4.1	28
10	Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 590-601.	4.1	8
11	Vascular aging in long-term survivors of testicular cancer more than 20 years after treatment with cisplatin-based chemotherapy. <i>British Journal of Cancer</i> , 2020, 123, 1599-1607.	6.4	19
12	Tumour biomarkers: association with heart failure outcomes. <i>Journal of Internal Medicine</i> , 2020, 288, 207-218.	6.0	27
13	Early ageing after cytotoxic treatment for testicular cancer and cellular senescence: Time to act. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102963.	4.4	12
14	Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer. <i>Investigational New Drugs</i> , 2020, 38, 1454-1462.	2.6	10
15	Long-term survivors of early breast cancer treated with chemotherapy are characterized by a pro-inflammatory biomarker profile compared to matched controls. <i>European Journal of Heart Failure</i> , 2020, 22, 1239-1246.	7.1	30
16	High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes. <i>JAMA Oncology</i> , 2020, 6, 528.	7.1	17
17	miR-371a-3p, miR-373-3p and miR-367-3p as Serum Biomarkers in Metastatic Testicular Germ Cell Cancers Before, During and After Chemotherapy. <i>Cells</i> , 2019, 8, 1221.	4.1	39
18	53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 153, 127-134.	1.4	56

#	ARTICLE	IF	CITATIONS
19	89Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake. <i>Clinical Cancer Research</i> , 2019, 25, 3517-3527.	7.0	34
20	Diagnosis and Treatment Monitoring of a Patient with Gastrointestinal Stromal Tumor by Next-Generation Sequencing and Droplet Digital Polymerase Chain Reaction Assay of a PDGFRA Mutation in Plasma-Derived Cell-Free Tumor DNA. <i>Oncologist</i> , 2019, 24, e387-e390.	3.7	5
21	Insulin-like factor 3, luteinizing hormone and testosterone in testicular cancer patients: effects of β -hCG and cancer treatment. <i>Andrology</i> , 2019, 7, 441-448.	3.5	6
22	A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. <i>Investigational New Drugs</i> , 2018, 36, 828-835.	2.6	8
23	Avenues to molecular imaging of dying cells: Focus on cancer. <i>Medicinal Research Reviews</i> , 2018, 38, 1713-1768.	10.5	30
24	89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. <i>Nature Medicine</i> , 2018, 24, 1852-1858.	30.7	468
25	Risk of diabetes after para-aortic radiation for testicular cancer. <i>British Journal of Cancer</i> , 2018, 119, 901-907.	6.4	14
26	Self-monitoring physical activity with a smartphone application in cancer patients: a randomized feasibility study (SMART-trial). <i>Supportive Care in Cancer</i> , 2018, 26, 3915-3923.	2.2	47
27	Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer. <i>British Journal of Cancer</i> , 2018, 119, 408-418.	6.4	50
28	ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, 1658-1686.	1.2	228
29	A single digital droplet PCR assay to detect multiple <i>KIT</i> exon 11 mutations in tumor and plasma from patients with gastrointestinal stromal tumors. <i>Oncotarget</i> , 2018, 9, 13870-13883.	1.8	28
30	Diastolic Dysfunction is Common in Survivors of Pediatric Differentiated Thyroid Carcinoma. <i>Thyroid</i> , 2017, 27, 1481-1489.	4.5	16
31	Tyrosine kinase inhibitor sensitive PDGFR β mutations in GIST: Two cases and review of the literature. <i>Oncotarget</i> , 2017, 8, 109836-109847.	1.8	8
32	Bleomycin-Induced Pulmonary Changes on Restaging Computed Tomography Scans in Two Thirds of Testicular Cancer Patients Show No Correlation With Fibrosis Markers. <i>Oncologist</i> , 2016, 21, 995-1001.	3.7	9
33	Cancer-drug induced insulin resistance: Innocent bystander or unusual suspect. <i>Cancer Treatment Reviews</i> , 2015, 41, 376-384.	7.7	48
34	Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors. <i>Annals of Oncology</i> , 2015, 26, 2305-2310.	1.2	61
35	Growth Differentiation Factor 15 (GDF-15) Plasma Levels Increase during Bleomycin- and Cisplatin-Based Treatment of Testicular Cancer Patients and Relate to Endothelial Damage. <i>PLoS ONE</i> , 2015, 10, e0115372.	2.5	37
36	Lipopolysaccharide-binding protein: a possible diagnostic marker for Gram-negative bacteremia in neutropenic cancer patients. <i>Intensive Care Medicine</i> , 2003, 29, 2157-2161.	8.2	42